

## **Combination treatment with targeted agents in CLL**

[\(S804\) HIGH RATE OF COMPLETE RESPONSE BUT MINIMAL RESIDUAL DISEASE STILL DETECTABLE AFTER FIRST-LINE TREATMENT COMBINING OBINUTUZUMAB AND IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA \(CLL\): ICLL07 FILO TRIAL](#)

Anne-Sophie Michallet, et al. [ABSTRACT](#)

### **Conclusion**

These preliminary results indicated that this 9 month « chemo-free » induction is associated with a high CR rate (41%) without excess of toxicity. However, the majority of the patients required subsequent immuno-chemotherapy because of detectable BM MRD.

[\(S805\) HIGH, DURABLE MINIMAL RESIDUAL DISEASE \(MRD\) NEGATIVITY WITH VENETOCLAX + RITUXIMAB IN RELAPSED/REFRACTORY CLL: MRD KINETICS AND RESPONSES IN CYTOGENETIC RISK GROUPS IN PTS FROM PHASE 3 MURANO STUDY](#)

Peter Hillmen, et al. [ABSTRACT](#)

### **Conclusion**

The robust PB MRD and high concordance with BM MRD with VenR confirms the value of PB MRD for correlation with clinical outcome in patients with R/R CLL treated with this regimen. VenR achieves high, early, deep and durable PB MRD– regardless of risk features, unlike BR. Some reemergence of MRD+, mainly intermediate ( $10^{-4}$  to